Using single protein biomarkers to predict health and disease in diverse patient populations: A new role for assessment of immunoglobulin free light chains

Mayo Clinic Proceedings

Volumn 87, Issue 6, 2012, Pages 505-507

  Drayson, Mark T ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN FREE LIGHT CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; UNCLASSIFIED DRUG;

CANCER SURVIVAL; CONFERENCE PAPER; ELECTROPHORESIS; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; LYMPHATIC SYSTEM DISEASE; MORTALITY; MYELOMA; NONHODGKIN LYMPHOMA; PROGNOSIS; PROTEIN URINE LEVEL; PROTEINURIA; RISK FACTOR; SERUM FREE LIGHT CHAIN;

EID: 84863500188     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.04.004     Document Type: Conference Paper

References (15)

1. Dispenzieri A, Katzmann JA, Kyle RA, et al. Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. Mayo Clin Proc. 2012;87(6): 517-523.
2. Bence Jones H. Papers on chemical pathology, lecture III. Lancet 1847;2(1247):88-92.
3. Parkes Weber F, Hutchison R, Macleod JJR. A case of multiple myeloma (myelomatosis) with Bence-Jones proteid in the urine (myelopathic albumosuria of Bradshaw, Kahler's Disease), and a summary of published cases of Bence-Jones albumosuria: With a report on the chemical pathology. Med Chir Trans. 1903;86:395-470.
4. Gally JA, Edelman GM. Physicochemical properties of Bence-Jones proteins in the form of L-chain dimers. Biochim Biophys Acta. 1965;94:175-182.
5. Grey HM, Mannik M, Kunkel HG. Individual antigenic specificity of myeloma proteins: Characteristics and localization to subunits. J Exp Med. 1965;121:561-575.
6. Drayson M, Begum G, Basu S, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: An analysis of patients receiving conventionaldose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood. 2006;108(6):2013-2019. (Pubitemid 44395015)
7. Solomon A. Bence-Jones proteins and light chains of immunoglobulins (first of two parts). N Engl J Med. 1976; 294(1):17-23.
8. Waldmann TA, Strober W, Mogielnicki RP. The renal handling of low molecular weight proteins, II: Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest. 1972;51(8):2162-2174.
9. Corcos D, Osborn MJ, Matheson LS, et al. Immunoglobulin aggregation leading to Russell body formation is prevented by the antibody light chain. Blood. 2010;115(2):282-288.
10. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47(4):673-680. (Pubitemid 32275810)
11. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory myeloma. Blood. 2001;97(9):2900-2902.
12. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2003;361(9356):489-491. (Pubitemid 36173716)
13. Dimopoulos M, Kyle R, Fermand JP, et al; International Myeloma Workshop Consensus Panel 3. Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011; 117(18):4701-4705.
14. Pardanani A, Lasho TL, Finke CM, et al. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol. 2012;30(10):1087-1094.
15. Phillips AC, Carroll D, Gale CR, Drayson M, Thomas GN, Batty GD. Lymphocyte sub-population cell counts are associated with the metabolic syndrome and its components in the Vietnam Experience Study. Atherosclerosis. 2010;213(1):294-298.